Nuestro centro ha logrado la segunda mejor valoración por parte de los pacientes de todos los hospitales de complejidad media de Salud Madrid, con un Índice de Satisfacción Global del 92,2%

Enhorabuena a la campaña “Con nombres y apellidos” de Grupo Español de Cáncer de Pulmón por este reconocimiento en los #12PremiosGEPAC .🏆

#Uniendoesfuerzos

Very proud to participate in this excellent paper in Extensive-Stage Small-Cell Lung Cancer. A Spanish multicenter study exploring personlized treatment inthis aggresive neoplasm. Fundación Jiménez Díaz UAM Autónoma Madrid OncoAlert Cáncer de Pulmón #LCSM #IIS -FJD

Excellent news, we have participated in both trials. Fundación Jiménez Díaz UAM Autónoma Madrid Cáncer de Pulmón #IIS -FJD# #LCSM

⭕Para M.Provencio, presidente del GECP👨‍⚕️ 'Se necesita mayor respaldo público e inversión para que la investigación siga siendo independiente 👉El papel de los grupos cooperativos de investigación es fundamental ' buff.ly/49H5BlO

Just published in eBioMedicine – The Lancet Discovery Science!
Ever wondered why some heavy smokers never develop lung cancer, even in old age, while others do at a young age?
thelancet.com/journals/ebiom…

These clinically relevant phenotypes likely model extreme sensitivity and resistance to tobacco's…

Los estudiantes de la #UAM que se han proclamado ganadores de la European Law Moot Court Competition comparten sus impresiones sobre la extraordinaria experiencia que han vivido.

#OrgulloUAM

👇🏻👇🏻👇🏻

Excelente ponencia. Grande Imanol Martínez Salas

Ha sido un placer participar en XX Abordaje Multidisciplinar del cáncer en la mesa de cáncer de pulmón con estos grandes expertos. Muchas gracias a los organizadores Alfredo Carrato Luis Paz-Ares Javier Cortes MD PhD. Todo un lujo. Fundación Jiménez Díaz UAM Autónoma Madrid #LCSM EGFR Resisters

JUST OUT on NEJM
Among patients with resected🧬ALK-positive #NSCLC 🫁of stage IB, II, or IIIA, adjuvant alectinib 💊

✅Significantly improved disease-free survival 🆚 platinum-based chemotherapy

nejm.org/doi/full/10.10…

Christian Rolfo gilberto lopes Narjust Florez, MD, FASCO Stephen V Liu, MD…

Editorial on ALINA (adjuvant alectinib for resected #ALK NSCLC) from Drs. Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Solange Peters in NEJM. Acknowledge discussions of survival, optimal duration, testing, and role of chemotherapy in the context of highly effective targeted therapy.

nejm.org/doi/full/10.10…

🟦 Todas las novedades terapéuticas de la mano de los expertos en #CáncerdePulmón en el #SimposioAMC

Gracias por todos los aprendizajes 🔬

Dr. Antonio Calles 🫁🚭 Paz-Ares's Lab AlejandroNavarro_MD charocampelo Manuel Dómine, MD, PhD

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - Bray - CA: A Cancer Journal for Clinicians - Wiley Online Library AACR #aacr24 acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

ADRIATIC trial: 1st Phase 3 of immunotherapy (Durvalumab) showing a statistically significant improvement in OS and PFS in LS-SCLC after concurrent chemoradiotherapy comparing with placebo. We have participated very actively in this trial. Fundación Jiménez Díaz #LCSM #SCLC OncoAlert

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM

astrazeneca.com/media-centre/p…

🟦 El jueves 11 de abril abordaremos todas las novedades terapéuticas de la mano de los expertos en #CáncerdePulmón en el #SimposioAMC

Si no tienes patrocinio para tu inscripción, contacta con [email protected] y te la gestionamos gratuitamente 🙂

RESERVA TU PLAZA ⤵️

S-REAL study: Spanish real-world data of Grupo Español de Cáncer de Pulmón on unresectable stage III NSCLC pts treated with durvalumab after CRT: Results are in line with the ph III PACIFIC trial showing lower incidence of important treatment-associated toxicities, such as pneumonitis. Fundación Jiménez Díaz

Adagrasib demonstrated a statistically significant in PFS and ORR vs docetaxel 2nd-line or later treatment in KRAS G12C-Mutated NSCLC patients . Very proud to participate in the pivotal confirmatory Trial (KRYSTAL-12). Fundación Jiménez Díaz KRASKickers #LCSM
news.bms.com/news/corporate…

Randomized phase 3 KRYSTAL-12 study of adagrasib vs docetaxel in #KRAS G12C NSCLC (post chemo/immunotheraly) meets PFS endpoint. OS pending maturity. Adagrasib has FDA accelerated approval - this is the confirmatory trial. Await data presentation.

news.bms.com/news/corporate…

The authors of a new Review Article address the issues that must be confronted if we are to integrate the use of wearable digital health technologies into clinical care in a way that provides an enduring benefit to patients. Read the full review: nej.md/3vjcGL1